Literature DB >> 9454698

Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines.

N A Kuklin1, M Daheshia, P C Marconi, D M Krisky, R J Rouse, J C Glorioso, E Manican, B T Rouse.   

Abstract

In this report the ability of enteric immunization with recombinant replication deficient (ICP4-/-) HSV expressing IFN gamma to generate protection and modulate mucosal and systemic immunity was evaluated. ICP4-/-HSV, ICP4-/-HSV expressing IL4, live replicating, and uv HSV were used as controls. Following enteric administration of live HSV, a Th1 cytokine response was induced in the spleen, while both Th1 and notable Th2 cytokine production were detected at mucosal sites. Modulation of mucosal and systemic immune response was achieved when nonreplicating recombinant HSV viruses expressing cytokines were used. Compared to the control replication defective viruses, decreased frequency of Th2 cytokine producing cells in Peyer's patches was observed following enteric administration of nonreplicating HSV expressing IFN gamma. When IFN gamma expressing virus was given enterically, modulation was observed at the systemic level, measured by ELISPOT for cytokine producing cells, ELISA from the in vitro restimulated splenic cell cultures, and by the increase of the IgG2a/IgG1 ratio in the serum. This report provides evidence that replication defective viruses expressing cytokine genes in contrast to uv HSV, are immunogenic when administered enterically and can generate significant immunomodulatory effects at the mucosal and systemic levels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9454698     DOI: 10.1006/viro.1997.8926

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 2.  Vaccines against genital herpes: progress and limitations.

Authors:  Lynda A Morrison
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  IL-4 mediated by HSV vector suppresses morphine withdrawal response and decreases TNFα, NR2B, and pC/EBPβ in the periaqueductal gray in rats.

Authors:  H Yi; T Iida; S Liu; D Ikegami; Q Liu; A Iida; D A Lubarsky; S Hao
Journal:  Gene Ther       Date:  2017-03-16       Impact factor: 5.250

4.  Inflammation and clearance of Chlamydia trachomatis in enteric and nonenteric mucosae.

Authors:  J U Igietseme; J L Portis; L L Perry
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

5.  Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication.

Authors:  Hong Wang; David J Davido; Heba H Mostafa; Lynda A Morrison
Journal:  Viruses       Date:  2022-04-22       Impact factor: 5.818

6.  Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.

Authors:  Richard Brans; Feng Yao
Journal:  BMC Microbiol       Date:  2010-06-03       Impact factor: 3.605

7.  In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model.

Authors:  J I Sin; J J Kim; J D Boyer; R B Ciccarelli; T J Higgins; D B Weiner
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 8.  Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.

Authors:  Michael W Ferenczy
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

9.  Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1.

Authors:  Henning Lauterbach; Kristen M Kerksiek; Dirk H Busch; Elena Berto; Aleksandra Bozac; Penelope Mavromara; Roberto Manservigi; Alberto L Epstein; Peggy Marconi; Thomas Brocker
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain.

Authors:  Shuanglin Hao; Marina Mata; Joseph C Glorioso; David J Fink
Journal:  Mol Pain       Date:  2006-02-17       Impact factor: 3.395

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.